Exploring the regulatory mechanism of intestinal flora based on PD-1 receptor/ligand targeted cancer immunotherapy
Serving as a pivotal immunotherapeutic approach against tumors, anti-PD-1/PD-L1 therapy amplifies the immune cells’ capability to eliminate tumors by obstructing the interaction between PD-1 and PD-L1. Research indicates that immune checkpoint inhibitors are effective when a patient’s gut harbors un...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1359029/full |
| _version_ | 1827304430621425664 |
|---|---|
| author | Xinran Gao Xinran Gao Xinran Gao Jingting Jiang Jingting Jiang Jingting Jiang |
| author_facet | Xinran Gao Xinran Gao Xinran Gao Jingting Jiang Jingting Jiang Jingting Jiang |
| author_sort | Xinran Gao |
| collection | DOAJ |
| description | Serving as a pivotal immunotherapeutic approach against tumors, anti-PD-1/PD-L1 therapy amplifies the immune cells’ capability to eliminate tumors by obstructing the interaction between PD-1 and PD-L1. Research indicates that immune checkpoint inhibitors are effective when a patient’s gut harbors unique beneficial bacteria. As such, it has further been revealed that the gut microbiome influences tumor development and the efficacy of cancer treatments, with metabolites produced by the microbiome playing a regulatory role in the antitumor efficacy of Immune checkpoint inhibitors(ICBs). This article discusses the mechanism of anti-PD-1 immunotherapy and the role of intestinal flora in immune regulation. This review focuses on the modulation of intestinal flora in the context of PD-1 immunotherapy, which may offer a new avenue for combination therapy in tumor immunotherapy. |
| first_indexed | 2024-04-24T17:36:36Z |
| format | Article |
| id | doaj.art-d5d7364be2db49c789dc826ae04a34de |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-24T17:36:36Z |
| publishDate | 2024-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-d5d7364be2db49c789dc826ae04a34de2024-03-28T04:53:50ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-03-011510.3389/fimmu.2024.13590291359029Exploring the regulatory mechanism of intestinal flora based on PD-1 receptor/ligand targeted cancer immunotherapyXinran Gao0Xinran Gao1Xinran Gao2Jingting Jiang3Jingting Jiang4Jingting Jiang5Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, ChinaJiangsu Engineering Research Center for Tumor lmmunotherapy, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, ChinaInstitute of Cell Therapy, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, ChinaDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, ChinaJiangsu Engineering Research Center for Tumor lmmunotherapy, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, ChinaInstitute of Cell Therapy, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, ChinaServing as a pivotal immunotherapeutic approach against tumors, anti-PD-1/PD-L1 therapy amplifies the immune cells’ capability to eliminate tumors by obstructing the interaction between PD-1 and PD-L1. Research indicates that immune checkpoint inhibitors are effective when a patient’s gut harbors unique beneficial bacteria. As such, it has further been revealed that the gut microbiome influences tumor development and the efficacy of cancer treatments, with metabolites produced by the microbiome playing a regulatory role in the antitumor efficacy of Immune checkpoint inhibitors(ICBs). This article discusses the mechanism of anti-PD-1 immunotherapy and the role of intestinal flora in immune regulation. This review focuses on the modulation of intestinal flora in the context of PD-1 immunotherapy, which may offer a new avenue for combination therapy in tumor immunotherapy.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1359029/fullPD-1anti-PD-1intestinal floraICIimmunotherapy |
| spellingShingle | Xinran Gao Xinran Gao Xinran Gao Jingting Jiang Jingting Jiang Jingting Jiang Exploring the regulatory mechanism of intestinal flora based on PD-1 receptor/ligand targeted cancer immunotherapy Frontiers in Immunology PD-1 anti-PD-1 intestinal flora ICI immunotherapy |
| title | Exploring the regulatory mechanism of intestinal flora based on PD-1 receptor/ligand targeted cancer immunotherapy |
| title_full | Exploring the regulatory mechanism of intestinal flora based on PD-1 receptor/ligand targeted cancer immunotherapy |
| title_fullStr | Exploring the regulatory mechanism of intestinal flora based on PD-1 receptor/ligand targeted cancer immunotherapy |
| title_full_unstemmed | Exploring the regulatory mechanism of intestinal flora based on PD-1 receptor/ligand targeted cancer immunotherapy |
| title_short | Exploring the regulatory mechanism of intestinal flora based on PD-1 receptor/ligand targeted cancer immunotherapy |
| title_sort | exploring the regulatory mechanism of intestinal flora based on pd 1 receptor ligand targeted cancer immunotherapy |
| topic | PD-1 anti-PD-1 intestinal flora ICI immunotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1359029/full |
| work_keys_str_mv | AT xinrangao exploringtheregulatorymechanismofintestinalflorabasedonpd1receptorligandtargetedcancerimmunotherapy AT xinrangao exploringtheregulatorymechanismofintestinalflorabasedonpd1receptorligandtargetedcancerimmunotherapy AT xinrangao exploringtheregulatorymechanismofintestinalflorabasedonpd1receptorligandtargetedcancerimmunotherapy AT jingtingjiang exploringtheregulatorymechanismofintestinalflorabasedonpd1receptorligandtargetedcancerimmunotherapy AT jingtingjiang exploringtheregulatorymechanismofintestinalflorabasedonpd1receptorligandtargetedcancerimmunotherapy AT jingtingjiang exploringtheregulatorymechanismofintestinalflorabasedonpd1receptorligandtargetedcancerimmunotherapy |